{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:42:01Z","timestamp":1774327321736,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81,870,662"],"award-info":[{"award-number":["81,870,662"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFE0113900"],"award-info":[{"award-number":["2018YFE0113900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.msard.2022.104248","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T14:07:21Z","timestamp":1666015641000},"page":"104248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["MOG antibody prevalence in adult optic neuritis and clinical predictive factors for diagnosis: A Chinese cohort study"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0752-6956","authenticated-orcid":false,"given":"Honglu","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanfen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaohui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.msard.2022.104248_bib0001","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.104248_bib0002","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1016\/j.ophtha.2020.01.027","article-title":"The course of visual recovery after optic neuritis: experience of the optic neuritis treatment trial","volume":"127","author":"Beck","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.msard.2022.104248_bib0003","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.msard.2022.104248_bib0004","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/WNO.0000000000000779","article-title":"Do myelin oligodendrocyte glycoprotein antibodies represent a distinct syndrome?","volume":"39","author":"Chen","year":"2019","journal-title":"J. Neuroophthalmol."},{"issue":"4","key":"10.1016\/j.msard.2022.104248_bib0005","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-igg in patients in the optic neuritis treatment trial","volume":"136","author":"Chen","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.msard.2022.104248_bib0006","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2018.05.014","article-title":"Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: a multicenter study in South China","volume":"321","author":"Chen","year":"2018","journal-title":"J. Neuroimmunol."},{"issue":"6","key":"10.1016\/j.msard.2022.104248_bib0007","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ophtha.2005.01.036","article-title":"Poor prognosis of visual outcome after visual loss from giant cell arteritis","volume":"112","author":"Danesh-Meyer","year":"2005","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.msard.2022.104248_bib0008","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/ene.13315","article-title":"Etiologies of acute demyelinating optic neuritis: an observational study of 110 patients","volume":"24","author":"Deschamps","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.104248_bib0009","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.msard.2022.104248_bib0010","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/bjophthalmol-2019-314845","article-title":"MOG-Ab prevalence in optic neuritis and clinical predictive factors for diagnosis","volume":"104","author":"Ducloyer","year":"2020","journal-title":"Br. J. Ophthalmol."},{"issue":"10","key":"10.1016\/j.msard.2022.104248_bib0011","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ophtha.2019.04.042","article-title":"Epidemiologic and clinical characteristics of optic neuritis in Japan","volume":"126","author":"Ishikawa","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.msard.2022.104248_bib0012","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jns.2010.07.011","article-title":"Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis","volume":"298","author":"Jarius","year":"2010","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2022.104248_bib0013","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflam."},{"issue":"1","key":"10.1016\/j.msard.2022.104248_bib0014","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflam."},{"issue":"10","key":"10.1016\/j.msard.2022.104248_bib0015","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ophtha.2018.03.041","article-title":"Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis","volume":"125","author":"Jitprapaikulsan","year":"2018","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.msard.2022.104248_bib0016","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain J. Neurol."},{"issue":"9451","key":"10.1016\/j.msard.2022.104248_bib0017","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2022.104248_bib0018","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jns.2018.11.029","article-title":"The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis","volume":"396","author":"Liu","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.msard.2022.104248_bib0019","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2022.104248_bib0020","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ophtha.2006.06.060","article-title":"Natural history of the visual impairment of relapsing neuromyelitis optica","volume":"114","author":"Merle","year":"2007","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.msard.2022.104248_bib0021","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2022.104248_bib0022","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: a literature review","volume":"27","author":"Shahmohammadi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104248_bib0023","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jns.2019.03.014","article-title":"Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: a cohort study in China","volume":"400","author":"Song","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2022.104248_bib0024","article-title":"Incidence of multiple sclerosis in China: a nationwide hospital-based study. The Lancet regional health","volume":"1","author":"Tian","year":"2020","journal-title":"Lancet Reg. Health West. Pac."},{"issue":"2","key":"10.1016\/j.msard.2022.104248_bib0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2022.104248_bib0026","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjophthalmol-2020-317524","article-title":"Clinical predictive factors for diagnosis of MOG-IgG and AQP4-IgG related paediatric optic neuritis: a Chinese cohort study","volume":"106","author":"Yang","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.msard.2022.104248_bib0027","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajo.2022.01.015","article-title":"Vision prognosis and associated factors of optic neuritis in dependence of glial autoimmune antibodies","volume":"239","author":"Yang","year":"2022","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.msard.2022.104248_bib0028","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00415-017-8651-4","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai","volume":"265","author":"Zhao","year":"2018","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2022.104248_bib0029","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/bjophthalmol-2017-311177","article-title":"Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients","volume":"102","author":"Zhao","year":"2018","journal-title":"Br. J. Ophthalmol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822007520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822007520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:39Z","timestamp":1761901479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822007520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":29,"alternative-id":["S2211034822007520"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104248","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MOG antibody prevalence in adult optic neuritis and clinical predictive factors for diagnosis: A Chinese cohort study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104248"}}